Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM23UQ9)

• Drug Name: ABT-122 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Psoriatic arthritis	FA21	Phase 2	[1]
Rheumatoid arthritis	FA20	Phase 2	[2]

• Cross-matching ID: TTD Drug ID: DM23UQ9

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[4]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[5]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[6]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[7]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[8]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[9]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[10]
Etanercept	DMCV109	Arthritis	FA20	Approved	[11]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[12]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[13]

Drug(s) Targeting Interleukin-17 (IL17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brodalumab	DMASDQ6	Plaque psoriasis	EA90.0	Approved	[14]
Bimekizumab	DMR9TF1	Plaque psoriasis	EA90.0	Approved	[15]
Ixekizumab	DMXW92T	Plaque psoriasis	EA90.0	Approved	[16]
CNTO-6785	DM6RQXB	Rheumatoid arthritis	FA20	Phase 2	[17]
CJM112	DMTSVJM	Acne vulgaris	ED80	Phase 2	[18]
COVA322	DM824EG	Psoriasis vulgaris	EA90	Phase 1/2a	[19]
SHR-1314	DMADNY3	Plaque psoriasis	EA90.0	Phase 1/2	[15]
ABBV-257	DMCZI8L	Rheumatoid arthritis	FA20	Phase 1	[1]
ALX-0761	DMJ8ACF	Psoriasis vulgaris	EA90	Phase 1	[19]
SCH-900117	DM7A6R5	Rheumatoid arthritis	FA20	Phase 1	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-17 (IL17)	TTG0MT6	IL17_HUMAN	Modulator	[3]
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Modulator	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02349451) A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate. U.S. National Institutes of Health.
• [3] DOI: 10.1136/annrheumdis-2015-eular.4042
• [4] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [5] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [6] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [7] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [8] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [9] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [10] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [11] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [12] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [13] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
• [17] Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [20] Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76.